Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CLYMBullishIndustry Newsnews

High materiality8/10

Climb Bio's CLYM116 Phase 1 data strengthens next IgA nephropathy steps

Sep 3, 2026, 2:41 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive Phase 1 safety and PK/PD results plus clear 2027 clinical milestones suggest potential re-rating if NAVIGATE-2 data meet expectations.

AI summary

What happened, with direct paths to the underlying reporting

Climb Bio released Phase 1 data for CLYM116, showing a ~29-day half-life and strong APRIL suppression that supports every-12-week dosing. The NAVIGATE-2 Phase 2 design targets IgA nephropathy with an 800 mg loading dose followed by 400 mg maintenance, plus autoinjector development for registrational testing. Key catalysts lie in 2026–2027 NAVIGATE-2 readouts and the potential Phase 3 launch in 2027, which could shift the valuation trajectory.

Phase 1 data shows favorable safety with no SAEs or dose-limiting toxicity.
320 mg dose suggests ~29-day half-life, enabling every-12-week dosing.
Single 320 mg dose suppresses free APRIL >90% and IgA/IgM 60–75% for 12 weeks.
NAVIGATE-2 Phase 2 plans 800 mg loading then 400 mg maintenance; autoinjector prep.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.